1770
N. Nishina, Y. Yamamoto
CLUSTER
for C13H17NO [M+]: 203.1305; found: 203.1308.
128.9 [d, J(13C–31P) = 11.6 Hz], 131.5 [d, J(13C–31P) = 2.5
Hz], 133.9 [d, J(13C–31P) = 1.7 Hz], 134.0 [d, J(13C–
31P) = 14.9 Hz], 134.2 [d, J(13C–31P) = 7.5 Hz], 160.7 [d,
J(13C–31P) = 5.0 Hz]. 31P NMR (121.5 Hz, CDCl3): d = 25.0.
IR (neat, ATR): 1584, 1572, 1473, 1459, 1435, 1278, 1247,
1101, 1011, 764, 747 cm–1. Anal. Calcd for C19H17AuClOP:
C, 43.49; H, 3.27; Cl, 6.76. Found: C, 43.62; H, 3.32; Cl,
6.75. ESI-HRMS: m/z calcd for C19H17AuClOP [M + Na]:
547.0263; found: 547.0267.
(E)-4-(4-Phenylbut-2-enyl)morpholine (3c): 1H NMR (300
MHz, CDCl3): d = 2.30–2.54 (4 H, m), 2.95 (2 H, dd,
J = 6.6, 0.9 Hz), 3.36 (2 H, d, J = 6.6 Hz), 3.70 (4 H, dd,
J = 4.8, 4.8 Hz), 5.54 (1 H, dtt, J = 15.2, 6.6, 1.3 Hz), 5.76 (1
H, dtt, J = 15.2, 6.6, 1.3 Hz), 7.11–7.23 (3 H, m), 7.23–7.33
(2 H, m). 13C NMR (75.5 Hz, CDCl3): d = 38.9, 53.5, 61.1,
67.0, 126.1, 127.3, 128.4, 128.5, 133.4, 140.2. IR (neat):
1603, 1495, 1453, 1116, 1003, 975, 865, 745 cm–1. HRMS
(EI): m/z calcd for C14H19NO [M+]: 217.1462; found:
217.1464.
ClAuPPh2(p-F3CC6H4) (4d): 1H NMR (600 MHz, CDCl3):
d = 7.48–7.60 (10 H, m), 7.64 (2 H, dd, J = 12.6, 7.8 Hz),
7.72 (2 H, dd, J = 7.8, 1.5 Hz). 13C NMR (75.5 Hz, CDCl3):
d = 121.4 [d, J(13C–31P) = 1.2 Hz], 126.0 [dq, J(13C–31P) =
11.8 Hz, J(13C–19F) = 3.7 Hz], 126.7 [q, J(13C–19F) = 81.3
Hz], 128.0, 129.5 [d, J(13C–31P) = 11.8 Hz], 132.4 [d, J(13C–
31P) = 2.5 Hz], 134.2 [d, J(13C–31P) = 8.8 Hz], 134.3 [d,
J(13C–31P) = 14.3 Hz]. 31P NMR (121.5 Hz, CDCl3):
d = 33.3. IR (neat, ATR): 1436, 1395, 1322, 1125, 1103,
1061, 1014, 838, 748, 708 cm–1. ESI-HRMS: m/z calcd for
C19H14AuClF3P [M + Na]: 585.0031; found: 585.0032.
ClAuPPh2(o-MeC6H4) (4h): 1H NMR (600 MHz, CDCl3):
d = 2.53 (3 H, s), 6.74 (1 H, ddd, J = 12.7, 7.7, 1.2 Hz), 7.18
(1 H, dd, J = 7.5, 7.5 Hz), 7.29–7.33 (1 H, m), 7.43 (1 H, ddd,
J = 7.5, 7.5, 1.4 Hz), 7.46–7.51 (4 H, m), 7.53–7.60 (6 H, m).
13C NMR (75.5 Hz, CDCl3): d = 22.6 [d, J(13C–31P) = 12.2
Hz], 126.3 [d, J(13C–31P) = 10.0 Hz], 126.8 [d, J(13C–
31P) = 60.2 Hz], 128.0 [d, J(13C–31P) = 63.8 Hz], 129.4 [d,
J(13C–31P) = 12.2 Hz], 131.8 [d, J(13C–31P) = 2.2 Hz], 132.0
[d, J(13C–31P) = 9.3 Hz], 132.1 [d, J(13C–31P) = 2.2 Hz],
133.0 [d, J(13C–31P) = 8.6 Hz], 134.5 [d, J(13C–31P) = 14.3
Hz], 142.0 [d, J(13C–31P) = 12.2 Hz]. 31P NMR (121.5 Hz,
CDCl3): d = 32.1. IR (neat, ATR): 1589, 1479, 1436, 1101,
997, 804, 751, 714 cm–1. Anal. Calcd for C19H17AuClP: C,
44.86; H, 3.37; Cl, 6.97. Found: C, 45.00; H, 3.60; Cl, 6.93.
ESI-HRMS: m/z calcd for C19H17AuClP [M + Na]:
531.0314; Found: 531.0314.
(E)-4-(Undec-2-enyl)morpholine (3d): 1H NMR (300 MHz,
CDCl3): d = 0.81 (3 H, t, J = 6.6 Hz), 1.03–1.43 (12 H, m),
1.95 (2 H, dt, J = 7.0, 6.6 Hz), 2.26–2.48 (4 H, m), 2.86 (2 H,
d, J = 6.6 Hz), 3.65 (4 H, dd, J = 4.6, 4.6 Hz), 5.39 (1 H, dt,
J = 15.2, 6.6 Hz), 5.54 (1 H, dt, J = 15.2, 6.6 Hz). 13C NMR
(75.5 Hz, CDCl3): d = 14.1, 22.7, 29.2, 29.2, 29.3, 29.4,
31.9, 32.3, 53.5, 61.4, 67.0, 125.6, 135.3. IR (neat): 1720,
1454, 1004, 972, 867 cm–1. HRMS (EI): m/z calcd for
C15H29NO [M+]: 239.2244; found: 239.2246.
(E)-4-(3-Cyclohexylallyl)morpholine (3e): 1H NMR (300
MHz, CDCl3): d = 0.98–1.31 (5 H, m), 1.55–1.85 (5 H, m),
1.85–2.03 (1 H, m), 2.34–2.55 (4 H, m), 2.93 (2 H, d, J = 6.8
Hz), 3.71 (4 H, dd, J = 4.7, 4.7 Hz), 5.40 (1 H, dtd, J = 15.4,
6.6, 0.9 Hz), 5.55 (1 H, dd, J = 15.4, 6.6 Hz). 13C NMR (75.5
Hz, CDCl3): d = 26.0, 26.1, 32.9, 40.5, 53.5, 61.5, 67.0,
123.0, 141.1. IR (neat): 1718, 1449, 1118, 1005, 971, 866
cm–1. HRMS (EI): m/z calcd for C13H23NO [M+]: 209.1775;
found: 209.1779.
(E)-4-(4,4-Dimethylpent-2-enyl)morpholine (3f): 1H NMR
(300 MHz, CDCl3): d = 0.94 (9 H, s), 2.27–2.44 (4 H, m),
2.87 (2 H, dd, J = 6.8, 1.0 Hz), 3.66 (4 H, dd, J = 4.7, 4.7
Hz), 5.32 (1 H, dt, J = 15.6, 6.8 Hz), 5.56 (1 H, d, J = 15.6
Hz). 13C NMR (75.5 Hz, CDCl3): d = 29.6, 29.7, 53.5, 61.5,
67.0, 120.3, 146.2. IR (neat): 1732, 1454, 1260, 1119, 1005,
975, 868 cm–1. ESI-HRMS: m/z calcd for C11H21NO [M +
H]: 184.1696; found: 184.1696.
1H, 13C, and 31P NMR chemical shifts are reported relative to
CDCl3 and 85% H3PO4.
(E)-4-(4-Phenylbut-3-en-2-yl)morpholine (3g): 1H NMR
(300 MHz, CDCl3): d = 1.24 (3 H, d, J = 6.6 Hz), 2.54 (4 H,
dt, J = 4.8, 4.4 Hz), 3.00 (2 H, dq, J = 8.1, 6.6 Hz), 3.71 (4
H, dd, J = 4.4, 4.4 Hz), 6.15 (1 H, dt, J = 15.8, 8.1 Hz), 6.44
(1 H, d, J = 15.8 Hz), 7.14–7.42 (5 H, m). 13C NMR (75.5
Hz, CDCl3): d = 17.8, 50.8, 63.1, 67.2, 126.2, 127.5, 128.6,
131.2, 132.1, 136.9. IR (neat): 1600, 1494, 1447, 1265,
1116, 963, 864, 747 cm–1. HRMS (EI): m/z calcd for
C14H19NO [M+]: 217.1462; found: 217.1465.
(16) General Procedure for Hydroamination of Allenes
To a suspension of [AuClPPh2(o-tolyl)] (25.4 mg, 0.05
mmol) in toluene (0.5 mL) was added morpholine (43.7 mg,
0.502 mmol). To the reaction mixture was added 4-methyl-
phenylallene (1a, 79.3 mg, 0.6 mmol) and the resulting
mixture was stirred at 80 °C under an Ar atmosphere. The
reaction mixture was colorless and heterogeneous at the
beginning, but it turned yellow to brown as the reaction
progressed. After the reaction was completed (12 h), the
reaction mixture was filtered through short Florisil® gel pad
with EtOAc as an eluent and the resulting filtered solution
was concentrated. The product was purified by column
chromatography (basic silica gel, hexane–EtOAc = 100:1 to
10:1) to give 3a in 83% yield (90.8 mg).
(E)-4-(1-Phenylbut-2-enyl)morpholine (3g¢): 1H NMR (300
MHz, CDCl3): d = 1.59 (3 H, dd, J = 6.0, 1.1 Hz), 2.15–2.31
(2 H, m), 2.33–2.56 (2 H, m), 3.48 (1 H, d, J = 8.6 Hz), 3.61
(4 H, dd, J = 4.4, 4.4 Hz), 5.45 (1 H, ddd, J = 15.0, 8.6, 1.1
Hz), 5.58 (1 H, dq, J = 15.0, 6.0 Hz), 7.11–7.31 (5 H, m). 13
NMR (75.5 Hz, CDCl3): d = 17.8, 52.0, 67.2, 74.6, 127.0,
127.7, 127.9, 128.5, 132.7, 142.3. IR (neat): 1492, 1449,
1271, 1116, 1003, 967, 875, 755 cm–1. ESI-HRMS: m/z
C
(17) (E)-4-(3-p-Tolylallyl)morpholine (3a): 1H NMR (300 MHz,
CDCl3): d = 2.31 (3 H, s), 2.40–2.59 (4 H, m), 3.12 (2 H, dd,
J = 6.8, 1.3 Hz), 3.72 (4 H, dd, J = 4.7, 4.7 Hz), 6.18 (1 H,
dt, J = 15.8, 6.8 Hz), 6.48 (1 H, d, J = 15.8 Hz), 7.10 (2 H, d,
J = 8.1 Hz), 7.25 (2 H, d, J = 8.1 Hz). 13C NMR (75.5 Hz,
CDCl3): d = 21.2, 53.7, 61.5, 67.0, 124.9, 126.2, 129.3,
133.3, 134.0, 137.4. IR (neat): 1712, 1512, 1452, 1116,
1006, 968, 869, 809, 776 cm–1. HRMS (EI): m/z calcd for
C14H19NO [M+]: 217.1462; found: 217.1464.
calcd for C14H19NO [M + H]: 218.1539; found: 218.1539.
4-(3-Phenylbut-2-enyl)morpholine (3h): inseparable
stereoisomeric mixture. 1H NMR (300 MHz, CDCl3):
d = 2.05 (E- and Z-3 H, s), 2.25–2.42 (Z-4 H, m), 2.44–2.60
(E-4 H, m), 2.91 (Z-2 H, d, J = 6.8 Hz), 3.17 (E-2 H, d,
J = 6.8 Hz), 3.70 (Z-4 H, dd, J = 4.6, 4.6 Hz), 3.72 (E-4 H,
dd, J = 4.6, 4.6 Hz), 5.55 (Z-1 H, td, J = 6.8, 1.3 Hz), 5.86
(E-1 H, td, J = 6.8, 1.3 Hz), 7.09–7.45 (E- and Z-5 H, m).
NOE Experiment for 3h: Two signals were observed by
irradiation for Me peak (d = 2.05 ppm); 0.52% for allyl-H
peak of E-isomer (d = 3.17 ppm) and 1.64% for vinyl-H
peak of Z-isomer (d = 5.55 ppm). From this experiment, we
determined that the major product was E-isomer and the E:Z
ratio was 5: 4.
4-Cinnamylmorpholine (3b): 1H NMR (300 MHz, CDCl3):
d = 2.45 (4 H, dd, J = 4.6, 4.6 Hz), 3.10 (2 H, dd, J = 6.8, 1.3
Hz), 3.68 (4 H, dd, J = 4.6, 4.6 Hz), 6.19 (1 H, dt, J = 15.8,
6.8 Hz), 6.47 (1 H, d, J = 15.8 Hz), 7.11–7.38 (5 H, m). 13
C
NMR (75.5 Hz, CDCl3): d = 53.7, 61.5, 66.9, 125.8, 126.3,
127.6, 128.6, 133.5, 136.7. IR (neat): 1598, 1496, 1451,
1277, 1115, 1006, 966, 868, 741 cm–1. HRMS (EI): m/z calcd
Synlett 2007, No. 11, 1767–1770 © Thieme Stuttgart · New York